Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$2.53 -3.1%	$2.05	$1.09 ▼ $7.22	$185.76M	2.97	1.63 million shs	544,478 shs
DAWN Day One Biopharmaceuticals	$6.97 -3.2%	$6.63	$5.64 ▼ $16.76	$737.51M	-1.26	2.11 million shs	879,101 shs
DNTH Dianthus Therapeutics	$23.41 -3.7%	$20.05	$13.36 ▼ $32.27	$782.18M	1.43	379,286 shs	264,707 shs
PROK ProKidney	$2.35 -2.5%	$2.32	$0.46 ▼ $7.13	$709.22M	1.76	2.54 million shs	1.12 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	0.00%	+6.10%	+15.49%	+89.13%	-60.69%
DAWN Day One Biopharmaceuticals	0.00%	+6.67%	-0.41%	+14.83%	-48.90%
DNTH Dianthus Therapeutics	0.00%	+17.16%	+13.02%	+31.92%	-14.13%
PROK ProKidney	0.00%	+2.12%	-26.75%	+239.15%	+0.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CCCC C4 Therapeutics	1.4825 of 5 stars	3.2	2.0	0.0	1.7	0.6
DAWN Day One Biopharmaceuticals	2.2553 of 5 stars	3.6	2.0	2.0	2.5	0.0
DNTH Dianthus Therapeutics	1.3339 of 5 stars	3.5	0.0	1.7	1.7	0.0
PROK ProKidney	3.7219 of 5 stars	4.2	4.0	1.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.33	Hold	$8.00	216.21% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$25.29	262.78% Upside
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	130.67% Upside
PROK ProKidney	2.33	Hold	$6.25	165.96% Upside

Current Analyst Ratings Breakdown

Latest CCCC, DAWN, PROK, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/18/2025	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$25.00
8/18/2025	PROK ProKidney	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.58M	5.06	N/A	N/A	$3.06 per share	0.83
DAWN Day One Biopharmaceuticals	$131.16M	5.44	N/A	N/A	$4.99 per share	1.40
DNTH Dianthus Therapeutics	$4.85M	155.24	N/A	N/A	$11.91 per share	1.97
PROK ProKidney	$80K	8,644.48	N/A	N/A	($3.41) per share	-0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$105.32M	-$1.58	N/A	N/A	N/A	-325.88%	-53.91%	-33.26%	10/30/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.57	N/A	N/A	N/A	N/A	N/A	-17.11%	11/11/2025 (Estimated)

Latest CCCC, DAWN, PROK, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PROK ProKidney	-$0.14	-$0.13	+$0.01	-$0.13	N/A	$0.22 million
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	$5.24 million	$6.46 million
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.06	5.06
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
DNTH Dianthus Therapeutics	N/A	13.12	13.12
PROK ProKidney	N/A	11.48	11.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
DAWN Day One Biopharmaceuticals	87.95%
DNTH Dianthus Therapeutics	47.53%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	8.73%
DAWN Day One Biopharmaceuticals	6.20%
DNTH Dianthus Therapeutics	8.15%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	150	71.17 million	64.96 million	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
DNTH Dianthus Therapeutics	80	32.19 million	26.86 million	Optionable
PROK ProKidney	3	294.28 million	172.18 million	Optionable

CCCC, DAWN, PROK, and DNTH Headlines

Recent News About These Companies

ProKidney (NASDAQ:PROK) Cut to Hold at Zacks Research

August 22 at 9:58 AM | marketbeat.com

ProKidney Corp. (NASDAQ:PROK) Sees Large Decline in Short Interest

August 21, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Shares Down 6.9% - What's Next?

August 21, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 8.1% - Here's What Happened

August 20, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 15, 2025 | marketbeat.com

ProKidney Reports 78 Percent Gain in Q2

August 14, 2025 | theglobeandmail.com

Citi Reaffirms Their Buy Rating on ProKidney (PROK)

August 14, 2025 | theglobeandmail.com

ProKidney reports larger second-quarter loss as key studies continue

August 14, 2025 | journalnow.comJ

ProKidney Corp. Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

ProKidney reports Q2 EPS (13c), consensus (14c)

August 12, 2025 | msn.com

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

August 12, 2025 | globenewswire.com

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts

August 10, 2025 | marketbeat.com

ProKidney Corp. (PROK) - Yahoo Finance

August 9, 2025 | finance.yahoo.com

ProKidney And 2 Other Penny Stocks To Watch Closely

August 7, 2025 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading Down 10.5% - What's Next?

August 7, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 10% - Should You Buy?

August 1, 2025 | marketbeat.com

ProKidney (PROK) to Release Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.8% - What's Next?

July 29, 2025 | marketbeat.com

ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed

July 25, 2025 | rhinotimes.comR

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

July 22, 2025 | msn.com

Meet the Biotech Stock That Rocketed 775% Higher

July 22, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, DAWN, PROK, and DNTH Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$2.53 -0.08 (-3.07%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 +0.04 (+1.58%)

As of 07:50 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.97 -0.23 (-3.19%)

Closing price 04:00 PM Eastern

Extended Trading

$6.98 +0.00 (+0.07%)

As of 06:34 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Dianthus Therapeutics NASDAQ:DNTH

$23.41 -0.89 (-3.66%)

Closing price 04:00 PM Eastern

Extended Trading

$23.42 +0.02 (+0.06%)

As of 04:10 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

ProKidney NASDAQ:PROK

$2.35 -0.06 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.39 +0.04 (+1.70%)

As of 07:44 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time